The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia
Open accessAbstract
Purpose.: A phase III, randomized study was carried out to establish the most effective and safest treatment to improve the primary endpoints of cancer cachexia—lean body mass (LBM), resting energy expenditure (REE), and fatigue—and relevant secondary endpoints: appetite, quality of life, grip strength, Glasgow Prognostic Score (GPS) and proinflammatory cytokines. Patients and Methods.: Three hundred thirty-two assessable patients with cancer-related anorexia/cachexia syndrome were randomly assigned to one of five treatment arms: arm 1, medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day); arm 2, oral supplementation with eicosapentaenoic acid; arm 3, L-carnitine (4 g/day); arm 4, thalidomide (200 mg/day); and arm 5, a combination of the above. Treatment duration was 4 months. Results.: Analysis of variance showed a significant difference between treatment arms. A post hoc analysis showed the superiority of arm 5 over the others for all primary endpoints. An analysis of changes from baseline showed that LBM (by dual-energy X-ray absorptiometry and by L3 computed tomography) significantly increased in arm 5. REE decreased significantly and fatigue improved significantly in arm 5. Appetite increased significantly in arm 5; interleukin (IL)-6 decreased significantly in arm 5 and arm 4; GPS and Eastern Cooperative Oncology Group performance status (ECOG PS) score decreased significantly in arm 5, arm 4, and arm 3. Toxicity was quite negligible, and was comparable between arms. Conclusion.: The most effective treatment in terms of all three primary efficacy endpoints and the secondary endpoints appetite, IL-6, GPS, and ECOG PS score was the combination regimen that included all selected agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions
Higdon, J. V., & Frei, B. (2003) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690390826464 · Cited by 1,854
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
McMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
Arends, J., Strasser, F., Gonella, S., Solheim, T. S., Madeddu, C., Ravasco, P., Buonaccorso, L., de van der Schueren, M. A. E., Baldwin, C., Chasen, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100092 · Cited by 586
Self-citationUnderstanding cachexia as a cancer metabolism syndrome
Porporato, P. E. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.3 · Cited by 562
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Metadata
- Authors
- Mantovani, G., Macciò, A., Madeddu, C., Serpe, R., Massa, E., Dessì, M., Panzone, F., & Contu, P.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-01
- Volume
- 15
- Issue
- 2
- Pages
- 200-211
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2126536849
- Cited by
- 231
- References
- 1
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia. https://app.cochat.ai/papers/10.1634/theoncologist.2009-0153
- The paper
- Mantovani, G., Macciò, A., Madeddu, C., Serpe, R., Massa, E., Dessì, M., Panzone, F., & Contu, P. (2010). Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia. The Oncologist. https://doi.org/10.1634/theoncologist.2009-0153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.